Biotech

I have sat in rooms where brilliant people could not find the slide. You know the moment. Someone asks a question that should be answerable, a decision made two years ago, a trial result from a compound that looked similar, a regulatory interaction that taught the team something important, and the…

Biotech is often described as capital intensive, high risk, and slow to mature. Those statements are all true, but they are also incomplete. What we are seeing now is not simply the consequence of a difficult sector. It is the result of a deeper misalignment between the nature of scientific…

Life sciences believe we are governed by data, rigor, probability curves, and Kaplan Meier plots.

The proposed removal of approximately $16.6 billion from science, research, public health, and innovation funding is often discussed as a policy issue. For biotechnology leaders, it is a structural risk issue.

Over the last several weeks, I have had a series of conversations with emerging biotech leaders that all landed in roughly the same place. Different companies. Different modalities. Different stages. Same underlying challenge.

Biotechnology is not a pipeline category or a procurement line. It is the upstream engine of scientific progress. It is an ecosystem built on platforms, talent, and the courage to pursue ideas that will not survive a traditional risk filter. Biotech is different. But the system around it is…

I strongly believe that biotech and pharma are different and nowhere is that clearer than in how the United States is responding to China in biotechnology. Biotech is increasingly being treated as strategic infrastructure, spanning manufacturing, data, platforms, and know-how. Pharma, meanwhile,…

Biotechnology was never meant to be a subset of traditional pharmaceuticals. That distinction mattered at the beginning, and it still matters today for United States competitiveness and, more importantly, for patients.